ArticleExpert opinion on drug discovery2011
Advances in tau-based drug discovery.
Article in Expert opinion on drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Toward common treatment strategies: convergent proteinopathies and mitochondrial dysfunction in Alzheimer's and Parkinson's diseases.Frontiers in neuroscience · 2026Review
- Photodynamic and Photothermal Therapies using Nanotechnology Approach in Alzheimer's Disease.Current neuropharmacology · 2025Review
- N-Acetylcysteine Amide against Aβ-Induced Alzheimer's-like Pathology in Rats.International journal of molecular sciences · 2023Article
- Hypothesis on ontogenesis and pathophysiology of Alzheimer's disease.Einstein (Sao Paulo, Brazil) · 2022Review
- Dichotomous role of microtubule associated protein tau as a biomarker of response to and a target for increasing efficacy of taxane treatment in cancers of epithelial origin.Pharmacological research · 2021Review
- Insight Into Seeded Tau Fibril Growth From Molecular Dynamics Simulation of the Alzheimer's Disease Protofibril Core.Frontiers in molecular biosciences · 2021Article
- The effect of insomnia on development of Alzheimer's disease.Journal of neuroinflammation · 2020Review
- Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies.NPJ vaccines · 2018Review
- Preparation of organotypic brain slice cultures for the study of Alzheimer's disease.F1000Research · 2018Article
- Tau Pathology in Parkinson's Disease.Frontiers in neurology · 2018Review
- Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2017Review
- Early glycogen synthase kinase-3β and protein phosphatase 2A independent tau dephosphorylation during global brain ischaemia and reperfusion following cardiac arrest and the role of the adenosine monophosphate kinase pathway.The European journal of neuroscience · 2016Article
- Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain.Acta neuropathologica communications · 2016Article
- Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.Frontiers in pharmacology · 2016Review
- Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?Oxidative medicine and cellular longevity · 2015Review
- The cellular distribution and Ser262 phosphorylation of tau protein are regulated by BDNF in vitro.PloS one · 2014Article
- Phosphorylation of tau protein over time in rats subjected to transient brain ischemia.Neural regeneration research · 2013Article
- Trans-splicing correction of tau isoform imbalance in a mouse model of tau mis-splicing.Human molecular genetics · 2013Article
- The importance of tau phosphorylation for neurodegenerative diseases.Frontiers in neurology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
introductionTauopathies, including Alzheimer's disease (AD) and some frontotemporal dementias, are neurodegenerative diseases characterised by pathological lesions comprised of tau protein. There is currently a significant and urgent unmet need for disease-modifying therapies for these conditions and recently attention has turned to tau as a potential target for intervention. AREAS COVERED: Increasing evidence has highlighted pathways associated with tau-mediated neurodegeneration as important targets for drug development. Here, the authors review recently published papers in this area and summarise the genetic and pharmacological approaches that have shown efficacy in reducing tau-associated neurodegeneration. These include the use of agents to prevent abnormal tau processing and increase tau clearance, therapies targeting the immune system, and the manipulation of tau pre-mRNA to modify tau isoform expression. EXPERT OPINION: Several small molecule tau-based treatments are currently being assessed in clinical trials, the outcomes of which are eagerly awaited. Current evidence suggests that therapies targeting tau are likely, at least in part, to form the basis of an effective and safe treatment for Alzheimer's disease and related neurodegenerative disorders in which tau deposition is evident.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.